Document and Entity Information Document Information [Table] Document Information [Line Items] Document Type Document Quarterly Report Document Transition Report Document Period End Date Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Amendment Flag Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Balance Sheets Statement [Table] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current assets Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Money Market Funds Debt Securities, Current Marketable debt securities Equity Securities, FV-NI Marketable equity securities Equity Securities with Readily Determinable Fair Value Accounts Receivable, Net, Current Accounts receivable Receivable Prepaid Expense and Other Assets, Current Prepaid expenses Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Intangible Assets, Net (Excluding Goodwill) Patents, licenses, and other intangible assets, net Debt Securities, Noncurrent Marketable debt securities - long term Equity Securities Noncurrent Marketable equity securities - long term Notes, Loans and Financing Receivable, Net, Noncurrent Notes receivable - long term Operating Lease, Right-of-Use Asset Right of use (ROU) asset Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and stockholders' equity Liabilities, Current [Abstract] Current liabilities Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Operating Lease, Liability, Current Lease liability - short-term Lease liabilities Contract with Customer, Liability, Current Deferred revenue Taxes Payable, Current Income tax payable Liabilities, Current Total current liabilities Operating Lease, Liability, Noncurrent Lease liability - long-term Lease liabilities, net of current portion Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity Preferred Stock, Value, Issued Preferred stock, $0.01 par value: 10,000,000 authorized shares; -0- issued and outstanding shares at September 30, 2022 and December 31, 2021 Common Stock, Value, Issued Common stock, $0.01 par value: 200,000,000 authorized shares at September 30, 2022 and December 31, 2021; 59,773,337 issued and outstanding at September 30, 2022 and 59,355,558 issued and outstanding at December 31, 2021 Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit) Accumulated deficit Stockholders' Equity Attributable to Parent Balance Balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Statements of Comprehensive Income (Loss) Revenues [Abstract] Revenue Revenue from Contract with Customer, Excluding Assessed Tax Collaborations, milestones, and royalties Revenue recorded Operating Expenses [Abstract] Operating expenses Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Nonoperating Income (Expense) [Abstract] Other income (expenses) Interest Income (Expense), Net Interest income, net Other Nonoperating Income (Expense) Other expense, net Other income Equity Securities, FV-NI, Gain (Loss) Net gains recognized on equity securities Net gain (loss) recognized on equity securities Gain (loss) on equity securities, net Nonoperating Income (Expense) Total other income (expense), net Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Income (loss) before income tax expense Income Tax Expense (Benefit) Income tax expense Net Income (Loss) Attributable to Parent Net income (loss) Other comprehensive loss Marketable Securities, Unrealized Gain (Loss) Net unrealized loss on marketable debt securities Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income (loss) Comprehensive income (loss) Net Income (Loss) Per Common Share Net income (loss) per share attributable to common stockholders: Earnings Per Share, Basic Basic net income (loss) per common share (in dollars per share) Earnings Per Share, Diluted Diluted net income (loss) per common share (in dollars per share) Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average shares used to compute net income (loss) per share attributable to common stockholders: Weighted Average Number of Shares Outstanding, Basic Basic (in shares) Weighted-average common shares outstanding used in computing basic net income (loss) Weighted Average Number of Shares Outstanding, Diluted Diluted (in shares) Weighted-average common shares outstanding used in computing diluted net income (loss) Statements of Stockholders' Equity Equity Components [Axis] Equity Component [Domain] Common Stock Additional Paid-in Capital Accumulated Other Comprehensive Income (Loss) Accumulated Deficit Increase (Decrease) in Stockholders' Equity Shares, Outstanding Balance (in shares) Balance (in shares) Stock Issued During Period, Value, New Issues Sale of common stock Proceeds from sale of common stock Stock Issued During Period, Shares, New Issues Sale of common stock (in shares) Total equity shares Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Issuance of common stock upon exercise of stock awards Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Issuance of common stock upon exercise of stock awards (in shares) Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Issuance of restricted stock units Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Issuance of restricted stock units (in shares) Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock under the Employee Stock Purchase Plan Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock under the Employee Stock Purchase Plan (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation Condensed Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net (loss) income Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net (loss) income to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Accretion (Amortization) of Discounts and Premiums, Investments Amortization of premium on marketable securities Share-based Compensation Stock-based compensation Total employee, director and non-employee stock-based compensation expense Noncash Project Abandonment Costs Abandonment of capitalized intangible assets Abandonment costs Amount of equity received in connection with the sale of financial assets. Equity Received In Connection With Sale Of Financial Assets Equity received in connection with sale of financial assets Equity Securities, FV-NI, Unrealized Gain (Loss) Change in fair value of equity securities Unrealized gain (loss) recognized on equity securities Amount of impairment related to equity securities. Equity Securities Impairment Impairment on equity securities Gain (Loss) on Disposition of Assets Loss on disposal of assets Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase Decrease Collaboration Partner Receivable Accounts receivable and contract asset Increase Decrease In Accrued Investment Interest Receivable Interest receivable from marketable debt securities Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expenses Increase (Decrease) in Income Taxes Payable Income taxes The increase (decrease) during the reporting period relating to lease liabilities and right of use (ROU) assets. Increase Decrease In Lease Liabilities and Right Of Use Assets Lease liabilities and ROU assets Increase (Decrease) in Contract with Customer, Liability Deferred revenue Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Cash flows from investing activities Payments to Acquire Marketable Securities Purchase of marketable securities Payments to Acquire Equity Securities, FV-NI Purchase of equity securities Proceeds from Sale of Property, Plant, and Equipment Proceeds from sale of property and equipment Payments to Acquire Intangible Assets Purchase of intangible assets Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Proceeds from Sale and Maturity of Available-for-sale Securities Proceeds from maturities and sale of marketable securities Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options Proceeds from issuance of common stock upon exercise of stock awards Proceeds from Stock Plans Proceeds from issuance of common stock from Employee Stock Purchase Plan Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents, end of period Cash and cash equivalents, beginning of period Supplemental Cash Flow Information [Abstract] Supplemental disclosures of cash flow information Supplemental Cash Flow Information Cash Paid [Abstract] Cash paid for: Interest Paid, Net Interest Income Taxes Paid, Net Income taxes Noncash Investing and Financing Items [Abstract] Supplemental disclosures of non-cash investing activities Debt Securities, Available-for-sale, Unrealized Gain (Loss) Unrealized loss on marketable securities Summary of Significant Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Summary of Significant Accounting Policies Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Fair Value of Financial Instruments Earnings Per Share [Text Block] Net Income (Loss) Per Common Share Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Comprehensive Income (Loss) Marketable Debt and Equity Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Marketable Debt and Equity Securities Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Leases Lessee, Operating Leases [Text Block] Leases Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Collaboration and Licensing Agreements Collaborative Arrangement Disclosure [Text Block] Collaboration and Licensing Agreements Income Taxes Income Tax Disclosure [Text Block] Income Taxes Subsequent Event Subsequent Events [Text Block] Subsequent Event Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Use of Estimates, Policy [Policy Text Block] Use of Estimates Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Intangible Assets Investment, Policy [Policy Text Block] Marketable Debt and Equity Securities New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Schedule of assets recorded at fair value Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of basic and diluted net income (loss) per common share Marketable Securities [Table Text Block] Schedule of marketable securities Investments Classified by Contractual Maturity Date [Table Text Block] Schedule of maturities of marketable securities Schedule of Unrealized Loss on Investments [Table Text Block] Schedule of unrealized losses on available-for-sale investments Tabular disclosure of equity securities with readily determinable fair value. Equity Securities, FV-NI [Table Text Block] Schedule of equity securities with readily determinable fair value Equity Securities without Readily Determinable Fair Value [Table Text Block] Schedule of equity securities without readily determinable fair value Gain (Loss) on Securities [Table Text Block] Schedule of net gains and losses Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of total employee, director and non-employee stock-based compensation expense recognized Schedule of Stock Options Roll Forward [Table Text Block] Summary of stock option activity Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of weighted average assumptions used for estimation of fair value of stock options Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Schedule of weighted average assumptions used for estimation of fair value of ESPP Nonvested Restricted Stock Shares Activity [Table Text Block] Summary of restricted stock unity activity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of operating lease liabilities maturities Lease, Cost [Table Text Block] Summary of lease costs and cash disclosures Tabular disclosure of revenue by major licensees. Schedule of Revenue by Major Licensees [Table Text Block] Schedule of revenue by licensees Disaggregation of Revenue [Table Text Block] Schedule of disaggregation of revenue Disclosure of finite-lived and indefinite-lived intangible assets, excluding goodwill, in total and by major class. Finite Lived And Indefinite Lived Intangible Assets By Major Class [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] In Process Intangible Assets [Member] In-process intangible assets Finite Lived and Indefinite Lived Intangible Assets by Major Class [Line Items] Patents, licenses, and other intangible assets Impairment of Intangible Assets (Excluding Goodwill) Impairment of intangible assets Amount of impairment loss or recovery related to marketable securities. Marketable Securities Impairment Losses And Recoveries Impairment loss or recoveries Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Level 1 Level 2 Financial Instrument [Axis] Financial Instruments [Domain] Corporate Securities Government Securities Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Money Market Funds Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value of Financial Instruments Available-for-sale Securities, Debt Securities Marketable Securities Total estimated fair value Assets, Fair Value Disclosure Total Fair Value Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net Income (Loss) Per Share Net Income (Loss) Available to Common Stockholders, Basic Net income (loss) attributable to common stockholders Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Effect of dilutive securities Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Securities excluded in calculation of EPS Debt Securities, Available-for-sale [Table] Investment Type [Axis] Investments [Domain] Cash and Cash Equivalents Balance Sheet Location [Axis] Balance Sheet Location [Domain] Primary financial statement caption encompassing marketable securities. Marketable securities Schedule of Available-for-sale Securities [Line Items] Schedule of Available-for-sale Securities This item represents the total cost of cash and cash equivalents and marketable securities. Cash and Cash Equivalents and Marketable Securities Amortized Cost Investments, amortized cost Investments Debt Securities, Available-for-sale, Amortized Cost Total amortized cost Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Gross unrealized gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Gross unrealized losses Available-for-sale Securities, Debt Maturities, Amortized Cost Basis, Fiscal Year Maturity [Abstract] Amortized Cost Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis Maturing in one year or less Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis Maturing within two years Available-for-sale Securities, Debt Maturities, Fair Value, Fiscal Year Maturity [Abstract] Estimate Fair Value Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value Maturing in one year or less Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value Maturing within two years Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value [Abstract] Fair value Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months Fair value, less than 12 months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer Fair value, 12 months or greater Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss [Abstract] Unrealized losses Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Unrealized losses, Less than 12 months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Unrealized losses, 12 months or greater Debt Securities, Trading, and Equity Securities, FV-NI [Table] Counterparty Name [Axis] Counterparty Name [Domain] Represents the information pertaining to Catabasis Pharmaceuticals, Inc. Astria/Catabasis Represents information pertaining to the counterparty, INmune Bio, Inc. (INmune). INmune Represents information pertaining to MiRagen/Viridian. Viridian Class of Stock [Axis] Class of Stock [Domain] Debt and Equity Securities, FV-NI [Line Items] Equity Securities Equity Securities without Readily Determinable Fair Value [Table] Preferred Stock Represents information pertaining to Zenas bio pharma. Zenas Bio Pharma Limited Equity Securities without Readily Determinable Fair Value [Line Items] Equity securities without readily determinable fair value Equity Securities without Readily Determinable Fair Value, Amount Equity Securities without Readily Determinable Fair Value Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Information relating to a Technology License Agreement. Technology License Agreement Represents information pertaining to the License Agreement. License Agreement Investment Owned, Balance, Shares Owned investment The amount shares or share options could be purchased for in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Share Value Purchase amount of share options or equity in noncash transaction Equity Securities, FV-NI, Realized Gain (Loss) Less: net gain recognized on sale of equity securities Net gains recognized on sale of equity securities Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Represents information pertaining to the 2013 Equity Incentive Plan. The 2013 Plan Represents information pertaining to the 2010 Equity Incentive Plan. The 2010 Plan Award Type [Axis] Equity Award [Domain] Stock options ESPP RSUs Range [Axis] Range [Domain] Maximum Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock-based compensation Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Total number of shares of common stock available for issuance Represents the annual percentage increase in maximum number of shares (or other type of equity) approved (usually by shareholders and board of directors), for awards under the equity-based compensation plan. Share Based Compensation Arrangement by Share Based Payment Award Annual Percentage Increase in Shares Authorized Annual percentage increase in shares of common stock available for issuance Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Awards issued under the plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Increase in shares of common stock available for issuance (in shares) Represents the annual increase in maximum number of shares (or other type of equity) approved (usually by shareholders and board of directors), for awards under the equity-based compensation plan. Share Based Compensation Arrangement by Share Based Payment Award Annual Increase in Shares Authorized Annual increase in shares of common stock available for issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Options granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Granted Represents the number of annual installment vesting periods. Number Of Annual Installment Vesting Period Annual installment vesting periods Income Statement Location [Axis] Income Statement Location [Domain] General and administrative Research and development Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of Shares subject to outstanding options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Balance at the end of the period (in shares) Balance at the beginning of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Options forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Options exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Exercisable options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price (Per Share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Balance at the end of the period (in dollars per share) Balance at the beginning of the period (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Options granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Options forfeited (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Options exercised (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted-average remaining contractual life Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted-average remaining contractual life of awards exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate intrinsic value of options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Aggregate intrinsic value of options exercisable Share Price Weighted average price Closing price of common stock (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average fair value of options granted (in dollars per share) Minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Weighted average assumptions for estimated fair value of employee stock options Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility, low end of range (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected volatility, high end of range (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, low end of range (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, high end of range (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term (years) Share-based Compensation, Allocation and Classification in Financial Statements [Abstract] Compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Period to recognize unamortized compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Unamortized compensation expense related to unvested options Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Ending balance Beginning balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Ending Balance Weighted Average Grant Date Fair Value, Beginning Balance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted Average Grant Date Fair Value, Forfeited Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Unamortized compensation expense related to unvested restricted stock units Lessee, Lease, Description [Table] Scenario [Axis] Scenario, Unspecified [Domain] Forecast Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Represents information pertaining to lease office and laboratory space in Monrovia, CA. Monrovia, CA - office and laboratory space Represents information pertaining to the original lease office and laboratory space in Monrovia, CA, in addition to the additional space as included in the amended lease agreement. Monrovia, CA - office and laboratory space with additional space Represents information pertaining to one lease office space in San Diego, CA. San Diego, CA - office space Represents information pertaining to the laboratory and office space in Pasadena, California. Pasadena, CA - office and laboratory space Lessee, Lease, Description [Line Items] Lessee, Operating Lease, Existence of Option to Extend [true false] Option to extend Represents the number of phases associated with a lease term. Phases of Lease Term Phases of lease term Leasehold Improvements, Gross Improvement allowance Lessee Leasing Arrangements, Operating Leases, Renewal Term Renewal term Right-of-Use Asset Obtained in Exchange for Operating Lease Liability ROU assets exchanged for operating lease liabilities Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year For the remainder of 2022 Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2023 Lessee, Operating Lease, Liability, Payments, Due Year Two 2024 Lessee, Operating Lease, Liability, Payments, Due Year Three 2025 Lessee, Operating Lease, Liability, Payments, Due Year Four 2026 Lessee, Operating Lease, Liability, Payments, Due Year Five 2027 Lessee, Operating Lease, Liability, Payments, Due after Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due Total undiscounted lease payments Amount of monetary allowance granted by the landlord to a tenant for operating lease. Lessee, Operating Lease, Liability, Tenant Allowance Less: Tenant allowance Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: Imputed interest Operating Lease, Liability Operating lease liabilities Present value of lease payments Operating Lease, Cost Operating lease cost Variable Lease, Cost Variable lease cost Lease, Cost Total lease costs Operating Lease, Payments Cash paid for amounts included in the measurement of lease liabilities Operating Lease, Weighted Average Remaining Lease Term Remaining lease term Operating Lease, Weighted Average Discount Rate, Percent Discount rate Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Represents information by type of potential milestones. Potential Milestones Type [Axis] Represents information by name of potential milestones. Potential Milestones Type [Domain] Represents information pertaining to development-based potential milestones. Development-based Represents information pertaining to regulatory-based potential milestones. Regulatory-based Represents information pertaining to sales-based potential milestones. Sales-based Represents information pertaining to the option and license agreement. Option and license agreement Information pertaining to a research and license agreement. Research and License Agreement Represents information pertaining to the Collaboration and License agreement. Collaboration and License Agreement Information relating to a Patent License Agreement. Patent License Agreement Represents information relating to second collaboration and license agreement. Second Collaboration And License Agreement [Member] Second Collaboration And License Agreement Information relating to a Second Technology License Agreement or Second Viridian Agreement). Second Technology License Agreement [Member] Second Technology License Agreement Represents information pertaining to Alexion Pharmaceuticals, Inc., with which the entity has entered into a option and license agreement. Alexion Pharmaceuticals, Inc. Represents information pertaining to Amgen, Inc., with which the entity has entered into a Collaboration and Option Agreement. Amgen, Inc. Represent information pertaining to Astellas. Astellas Represent information pertaining to Genetech. Genentech Represents information pertaining to Janssen Biotech, Inc. Janssen Biotech, Inc Represents information relating to Johnson & Johnson Innovation, JJDC, Inc. Johnson & Johnson Innovation, JJDC, Inc. Represents information pertaining to MorphoSys. MorphoSys Represents information pertaining to Novartis. Novartis Information pertaining to VIR Biotechnology (VirBio). Vir Information pertaining to collaboration and licensing programs within the various agreements Collaboration and Licensing Programs [Axis] Information pertaining to collaboration and licensing programs within the various agreements Collaboration and Licensing Programs [Domain] Product and Service [Axis] Product and Service [Domain] Represents information pertaining to product XmAb24306. XmAb24306 Represent information pertaining to research activity. Research service Royalties Payment for achievement or success. Milestone Payment for development related milestones. Development Right to collaboration or assist on a project or agreement. Research collaboration Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaboration research and licensing agreements Number of antibodies selected for further development as per the agreement. Collaborative Arrangement, Number of Antibodies for Further Development Number of antibodies Represents the percentage of share assumed by the counter-party for development costs. Collaborative Agreement Share Percentage Of Development Cost, By Counterparty Share development percentage Represents the amount of nonrefundable upfront fees as provided under the collaboration agreement. Collaborative Arrangement Nonrefundable Upfront Fees Nonrefundable upfront payment Represents the amount of consideration that will be recognized upon full completion of milestones set forth in a collaborative agreement between two parties. Revenue Recognition Milestone Method Pending Potential milestone payment The initial cost-sharing percentage. Initial Cost-sharing Percentage Initial cost-sharing percentage Represents the research license term under the collaborative agreement. Collaborative Arrangement Research License Term Research license term Contract with Customer, Liability, Revenue Recognized Revenue recognized Contract with Customer, Asset, Net Contract asset Contract with Customer, Liability Deferred revenue Represents the amount of interest held in a private company. Collaborative Arrangement Percentage Equity Private Company Percentage of equity of private company Term of weighted average price of stock. Term of Volume Weighted Average Stock Price Term of weighted average price of stock Amount of receivable (payable) within a collaborative agreement that is associated with cost-sharing development activities. Collaborative Arrangement Receivable Payable Related To Cost Sharing Development Activities Cost sharing receivable (payable) Represents the number of candidates for which bispecific drug developed. Collaborative Agreement, Bispecific Drug Development, Number Of Candidates Number of drug candidates Represents the number of different target programs under the collaborative agreement. Collaborative Arrangement Number of Target Programs Number of different target programs The volume-weighted average per share price. Volume Weighted Average Share Price Volume-weighted average per share price Represents the percentage of responsibility assumed for development costs, if the company elects to participate in development. Collaborative Agreement, Percentage of Responsibility Assumed for Development Costs Percentage of responsibility for development costs Number of collaboration and license agreement. Number Of Collaboration And License Agreement Number of collaboration and license agreements Represents information pertaining to Janseen Janssen Effective Income Tax Rate Reconciliation, Amount [Abstract] Reconciliation of federal statutory income tax to effective income tax Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Events Warrant Convertible Note Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount Increase in equity securities